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immunoglobulin GAbstract Aim: To measure the level of VDBP (vitamin D binding protein) and serum 25-hydroxy
vitamin D (25OHD) in order to assess its role as a nutritional marker in cystic fibrosis (CF). The
relationship between vitamin DBP and immunoglobulin G (IgG) levels was assessed as well.
Methods: This is a cross-sectional observational study recruiting 50 patients diagnosed as having
CF from the Allergy and Pulmonology Unit, Children’s Hospital, Cairo University, from May
2012 until May 2013, twenty age- and sex-matched healthy children were included as a control
group. Vitamin DBP and 25OHD were measured using Elisa technique and total IgG was measured
using the nephelometer method.
Results: The CF group had significantly lower serum concentrations of DBP (p< 0.012) and
25OHD (p< 0.001) while IgG levels were within normal values (p< 0.216) compared to the
control group, patients with failure to thrive (FTT) have significantly lower levels of 25OHD and
significantly higher levels of VDBP and nearly the same level of IgG. Patients with pancreatic
insufficiency have significantly higher serum levels of VDBP.
Conclusions: The present study has demonstrated that the levels of 25OHD and VDBP are
decreased in CF patients while IgG levels are within normal values. In addition, the serum level
of 25OHD was significantly lower in patients with FTT, also significant relations of VDBP with
failure to thrive and pancreatic insufficiency were noted, emphasizing its role as a marker for the
nutritional status in CF patients. As a component of anti-inflammatory and nutritional therapy,
vitamin D is a predictor for clinical outcomes.
 2016 The Egyptian Pediatric Association. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ail.com
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Table 1 Demographic and clinical data of the study
population.
Characteristic N= 50 %
Age in years
Median 3
Range 1.5–13
Female 15 30
Male 35 70
Positive consanguinity 30 60
Family history of CF 11 22
Cough 47 94
Recurrent pneumonia 38 76
Recurrent wheezing 32 68
Recurrent hospital admission 47 94
Steatorrhea 32 64
Hepatomegaly 15 30
Failure to thrive 20 40
Clubbing 12 24
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Cystic fibrosis (CF) is the most common inherited disorder in
childhood, involves several organ systems, and results in life-
long morbidity and premature mortality. Lung disease in CF
is the major cause of death through a complex process involv-
ing impairment of mucociliary clearance, infection, inflamma-
tion and structural injury.1 Environmental, nutritional and
socio-economic factors as well as modifier genes may affect
the clinical manifestations of the disorder.2 Chronic inflamma-
tion has a negative impact on bone metabolism and has been
linked to impaired linear growth and bone mineral status.3
Vitamin D has long been known to play a critical role in the
maintenance of serum calcium levels and bone health. More
recently, there has been a growing appreciation of its potential
role in respiratory disease. Vitamin D deficiency results in
decreased lung volume in animal models, and it has also been
shown to have wide-ranging effects on immune functions.4,5
Recent data suggest that vitamin D deficiency modifies the
severity of a variety of lung diseases, including asthma, chronic
obstructive pulmonary disease and pneumonia.6–8
Hypovitaminosis D is almost universal in CF patients,
likely due to a combination of inadequate absorption,
impaired metabolism and a lack of sun exposure. Inadequate
levels are associated with the high prevalence of bone disease
or osteoporosis in CF patients, which is associated with
increased morbidity including fractures, kyphosis and worsen-
ing of the pulmonary status. For these reasons, screening for
and treatment of vitamin D deficiency is a critical component
of CF care.9
The physiology of vitamin D transport presents a challenge
in designing and interpreting studies of the association between
vitamin D status and pulmonary outcomes. Both 25 hydroxy
vitamin D (25OHD) and 1,25 dihydroxy vitamin D
(1,25OH2D) are bound in circulation to vitamin D-binding
protein (VDBP) and, to a lesser extent, to albumin. VDBP
gene polymorphisms may impact on VDBP levels as well as
binding of vitamin D to VDBP.10
The effects of low VDBP on vitamin D levels and metabo-
lism are not entirely clear. However, most 25 hydroxy vitamin
D (25OHD) is carried by VDBP and very little is free in serum.
High concentrations of unbound VDBP in normal patients
may function as a reservoir for 25OHD.11
The hallmark of CF is chronic lung inflammation. The
severity of lung disease is closely correlated with immunoglob-
ulin G (IgG) levels. The Scandinavian CF Nutritional Study
found an inverse relationship between vitamin D and serum
IgG levels.12
Since no studies have assessed whether vitamin D status has
an impact on inflammation or clinical outcomes in Egyptian
CF, we aimed in this study to evaluate the serum levels of
25OHD, the free VDBP and the level of IgG in Egyptian
patients with CF and correlate them with their nutritional
status.
Methods
This is a cross-sectional observational case-control study
including 50 CF patients. Diagnosis of CF was made based
on the clinical presentations of (Chronic lung disease, steator-
rhea, failure to gain weight) and confirmed by elevated sweatchloride testing above 60 meq/L. Patients were recruited from
the Allergy and Pulmonology Unit, specialized Children’s
Hospital, Cairo University, over a period of one year from
May 2012 until May 2013. Their ages ranged from 18 months
to 12 years. Twenty (20) age- and sex-matched healthy children
were included as a control group.
The protocol for the research project was approved by the
Ethics Committee of the specialized Children’s Hospital, Cairo
University and it conforms to the provisions of the Declara-
tion of Helsinki (as revised in 2000). Informed consent was
obtained from the parents after explanation of the aim of the
study.
Blood samples were collected by venipuncture, and serum
was separated and frozen at 20 C. The serum level of
DBP and serum level of 25OHDwere measured using the
Quantikine Human Vitamin D Binding Protein immunoassay
ELISA from R&D Systems, USA.13 The serum level of
immunoglobulin G (IgG) was measured nephelometrically
using Antisera to Human Immunoglobulins (NAS IGG) from
BN Prospec Siemens Healthcare Diagnostics Inc, Germany.14
The results were plotted and correlated with each other.
Results
Data management and analysis were performed using Statisti-
cal Package for Social Sciences (SPSS) version 17. Numerical
data were summarized using medians and ranges. Categorical
data were summarized as percentages. Comparisons between
the two groups were done using the Mann–Whitney test, a
non-parametric test equivalent to the t-test used in non-
normally distributed variables. To measure the strength of
the association between the numeric variables, Spearman’s
correlation coefficients were calculated.15 All p-values are
two-sided. P-values 6 0.05 were considered significant.
Data were collected for 50 CF children and 20 healthy age-
and sex-matched children as controls. Their ages ranged from
1.5 to 12 years and 30% were girls. The rate of consanguinity
was 60% and positive family history was 22% as shown in
Table 1. Most of the patients (94%) presented with cough,
76% with recurrent pneumonia, 68% with recurrent wheezing,
40% with failure to thrive and 64% with steatorrhea.
Table 2 Values of serum 25OHD, VDBP and IgG in cystic fibrosis (CF) patients compared to controls.
CF patients (n= 50) Controls (n= 20) p-Value*
Median Range Median Range
25OHD levels (ng/ml) 20.4 0.2–130.0 48.3 16.2–120.0 <0.001
VDBP levels (lg/ml) 273.6 80.6–633.4 320.6 240.6–495.8 0.012
IgG levels (g/l) 10.0 3.7–20.3 8.2 4.6–15.2 0.216
* P-values 6 0.05 are considered significant.
Figure 2 The median serum concentrations vitamin DBP
(vitamin D binding protein in lg/ml) in cases and controls.
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the CF group were significantly lower than their matched con-
trols (p< 0.05). There were 31 out of 50 patients (62%) with
low serum 25OHD levels below 30 ng/ml, 16 of them had
25OHD insufficiency (10–29 ng/ml) and 15 had 25OHD defi-
ciency (<10 ng/ml). Although serum IgG level was lower in
the cases than the controls, the difference was not significant,
as shown in Table 2.
The median serum concentrations of 25OHD levels, VDBP
and serum IgG in cases and controls are illustrated in
Figs. 1–3, respectively.
Comparison between the levels of VDBP, 25OHD and
serum IgG in CF patients with failure to thrive (FTT)(weight
and height for age are below the fifth percentile) and those
who are thriving well showed that patients with FTT have sig-
nificantly lower levels of 25OHD, significantly higher levels of
VDBP and nearly the same level of IgG, as shown in Table 3.
On comparing the levels of VDBP, 25OHD and serum IgG
in CF patients with pancreatic insufficiency (PI) and those who
are pancreatic sufficient (PS), it was found that patients with
PI have significantly higher levels of VDBP, with no other sta-
tistical significance between the two groups, as shown in
Table 4.
Discussion
This study revealed the presence of hypovitaminosis D as well
as its carrier protein VDBP in Egyptian patients with CF as
there were significantly low serum levels of 25OHD
(P< 0.001) and VDBP (P= 0.012) in the studied population
compared to their healthy matched controls: we found thatFigure 1 The median serum concentrations of 25OHD (25
hydroxy vitamin D in ng/ml) levels in cases and controls.
Figure 3 The median concentrations of serum IgG
(immunoglobulin G in g/l) in cases and controls.62% had low 25OHD levels, with nearly 50% of them having
a severe deficiency of 25OHD (serum level > 10 ng/ml). Defi-
ciency of 25OHD is universal in all CF patients, however its
degree may vary from one ethnic group to another. In 2007,
Rovner and colleagues found that 90% of pediatric patients
with CF were vitamin D insufficient.16 Similarly, Brodlie and
colleagues found that 90% of their pediatric CF population
was vitamin D insufficient, and after increasing the supplemen-
tation dose, 49% remained insufficient.17 Another study in
2010 in Denmark on 896 CF patients showed that 84% had
a suboptimal 25OHD level (<30 ng/ml).18
Also there was no significant correlation between serum
25OHD and VDBP. This was in accordance with a study
Table 3 Serum level of 25OH, VDBP and IgG in cystic fibrosis (CF) patients with failure to thrive (FTT) compared to those who are
thriving well.
Thriving well (n= 30) FTT (n= 20) p-Value*
Median Range Median Range
VDBP (lg/ml) 238.0 80.6–633.4 306.7 149.2–468.0 0.023
25OHD (ng/ml) 31.7 4.2–81.8 9.9 0.2–130.0 0.003
IgG (g/l) 9.8 3.7–20.3 10.0 5.6–17.1 0.898
* P-values 6 0.05 are considered significant.
Table 4 Serum level of 25OHD, VDBP and IgG in CF patients with PIy compared to PS.
PIy (n= 32) PS (n= 18) p-Value*
Median Range Median Range
VDBP (lg/ml) 306.7 82.2–633.4 237.0 80.6–461.0 0.039
25OHD (ng/ml) 20.4 0.2–130 20.8 3.7–54.7 0.944
IgG (g/l) 8.9 5.0–20.3 10.7 3.7–16.1 0.332
PIy: pancreatic insufficiency.
PS: pancreatic sufficiency.
* P-values 6 0.05 are considered significant.
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that investigated the importance of VDBP and its role as an
alternative nutritional marker in CF,19,20 while in the large
cohort study done by Carpenter et al. in 2012 on Caucasians
and Hispanics with CF it was shown that circulating DBP
was significantly correlated with 25OHD.21
In the present study, CF patients with failure to thrive
showed significantly lower serum levels of both 25OHD and
VDBP than those with normal weight gain. This could be
explained by severe malabsorption status in those with pancre-
atic insufficiency.
A more recent systematic review in 2013 summarized the
evidence on the relationship between vitamin D alone or in
combination with calcium and selected health outcomes
included in the earlier reviews. It showed that it is difficult to
make any substantive statements on the basis of the available
evidence concerning the association of either serum 25OHD
concentration, vitamin D supplementation, calcium intake or
the combination of both nutrients with the various health out-
comes because most of the findings were inconsistent.22
Meanwhile in our study, we found there was no significant
difference between median serum concentrations of IgG in the
CF and control groups (p= 0.216), and that serum IgG level
increases with age. Similar results were obtained from a recent
study carried out in Brazil in 2013 comparing the immunologic
state of CF children aged 3 to 12 years with a control group
where serum IgG was nearly the same in both groups.23 In
an old study conducted in Boston, USA, on 419 CF patients,
it was observed that patients under 10 years of age had
decreased IgG; however, older subjects showed normal or
higher levels. The authors concluded that, with the progression
of the pulmonary disease, these patients become more
susceptible to developing hypergammaglobulinaemia.24
Furthermore, serum IgG was neither correlated with FTTnor the PI status, which reflects the improved immunological
condition of patients with CF nowadays due to early diagnosis
and proper management.Conclusion
The present study has demonstrated that 25OHD and VDBP
levels are decreased in CF patients while IgG levels are within
normal values. In addition, the serum level of 25OHD was sig-
nificantly lower in patients with FTT.
Vitamin D is a valuable component of CF therapy as it
boosts the innate response yet limits excess inflammation.
Understanding the mechanisms by which vitamin D benefits
individuals with CF is still in its initial phases.
Therefore monitoring and annual screening of VDBP and
25OHD levels with aggressive treatment of those with low
levels is essential to prevent adverse long-term consequences.
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